1 / 33

IMAGING in ONCOLOGY

Gastro-oncology M Peeters N Van Damme V Casneuf. Biomedical Engineering P Verdonck D De Naeyer S Staelens. Surgical Oncology W Ceelen I Debergh. IMAGING in ONCOLOGY. Radiology P Smeets. Nuclear Medicine C Van De Wiele. Radiotherapy T Boterberg. Imaging of Angiogenesis.

jenna
Télécharger la présentation

IMAGING in ONCOLOGY

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Gastro-oncology M Peeters N Van Damme V Casneuf Biomedical Engineering P Verdonck D De Naeyer S Staelens Surgical Oncology W Ceelen I Debergh IMAGING in ONCOLOGY Radiology P Smeets Nuclear Medicine C Van De Wiele Radiotherapy T Boterberg

  2. Imaging of Angiogenesis • Direct: In Vivo Microscopy; molecular probes • Indirect • Blood volume • Vessel surface area • Vessel permeability • Vessel ‘normalization’

  3. Neoplastic vessels are morphologically and functionally deficient • Highly irregular and tortuous • Dependent on cell survival factors (VEGF) • Hyperpermeable • deficient pericyte coverage • absence of a basement membrane • deficient intercellular junctions • presence of cellular lacunae • vascular mimicry • Resulting in abnormal microenvironment: hypoxia, low pH, interstitial hypertension

  4. Corrosion casting – SEM; Konerding et al. BJC2001

  5. Hyperpermeability of tumor vessels is important • Results in increased interstitial fluid pressure • Enhances macromolecular leakage • Permeability change is a surrogate marker of angiogenesis

  6. The concept of vessel normalisation by anti-angiogenic therapy • Return to ‘normal’ phenotype by vascular pruning • Results in more efficient drug delivery by lowering IFP and restoring microvessel function  paradoxical synergism of anti-angiogenesis agents and cytostatic drugs • Results in more efficient RT by enhanced oxygenation

  7. Bevacizumab normalises rectal cancer microvessels Willett et al. NATURE MEDICINE VOLUME 10 | NUMBER 2 | FEBRUARY 2004

  8. Known Effects of Radiotherapy on tumor vessels • Induces endothelial cell apoptosis • Induces EC ‘senescent’ phenotype • Stimulates production of endothelin • Effects on vascular permeability dependent on dose, fractionation, tissue type • Direct or bystander effect?

  9. Apoptosis resistant TUNEL Garcia-Barros et al. Tumor Response to Radiotherapy (15 Gy) Regulated by Endothelial Cell Apoptosis. Science 2003

  10. How does anti-angiogenic therapy increase radiotherapy efficacy? • Inhibits protective VEGF signaling from tumor  EC • Enhances oxygenation • Reduces number of circulating EC and progenitor cells

  11. Phase I trials combining neoadjuvant CRT with anti-angiogenic therapy in rectal cancer • Czito IJROBP 2007 • 11 patients, 50.4 Gy, capecitabine,oxaliplatin, and bevacizumab • Acceptable toxicity • 18% pCR; 27% microscopic disease • Willett JCO 2005 • 5 patients, 50.4 Gy, 5-FU, bevacizumab 10 mg/kg • 2 complete responses seen in patients with DLT

  12. Functional imaging using Dynamic Contrast Enhanced MRI • Inject contrast agent bolus • Acquire a series of MR images over time with sufficient temporal resolution • Measure signal intensity changes as a consequence of leakage of CA from the vascular compartment into the interstitial space

  13. DCE-MRI Data Analysis • Description of enhancement curve • Semi-quantitative approach: AUC, TTP, maximal enhancement • Pharmacokinetic compartmental models • Statistical models

  14. Enhancement curve evaluation in DCE-MRI

  15. Farmacokinetic models in DCE-MRI Tofts St Lawrence - Lee

  16. Physiological significance of calculated endothelial transfer constant • Small MW contrast agent: flow >> permeability • Large MW contrast agent (preclinical): permeability >> flow

  17. Oncology Imaging Research @ UZ Gent • Preclinical • DCE-MRI • Rat colorectal cancer model • Mouse pancreas cancer model • Molecular MRI • Sequence optimisation; simulation; modelling • In vivo flurescence microscopy • Hamster melanoma and pancreas cancer model • Human CRC model in athymic mouse • Clinical • DCE-MRI in metastatic CRC treated with folfox-bevacizumab • USPIO in advanced solid tumors In collaboration with research dept. of Guerbet SA

  18. Effects of RT on neovascular permeability measured with DCE-MRI using P792 Ktrans (1/min) After RT Before RT Ceelen et al. Int J Radiat Oncol Biol Phys 2006

  19. rhEPO prevents radiotherapy-induced reduction in neovascular permeability Ceelen et al. Br J Cancer 2007

  20. Molecular imaging by targeting αvβ3 integrin Arg-Gly-Asp (RGD) peptide Beta 3 integrin

  21. Pre 20 min Post Molecular imaging in HT29 tumors using a αvβ3 integrin targeted MR probe Debergh I, Van Damme N, Smeets P, Peeters M, Pattyn P, Ceelen W. Molecular imaging of tumor associated angiogenesis using P1227, a novel MRI contrast agent targeting avb3 integrin. Br J Surg 2008;95 Suppl 6: 13.

  22. Dorsal Skin Window Chamber model

  23. Collaboration with the biomedical engineering department • Modelling of the AIF in DCE-MRI (PhD student) • D De Naeyer et al. Modelling the arterial input function for P792 in dynamic contrast enhanced magnetic resonance imaging: concepts and validation. Submitted, MRM • Modelling interstitial fluid pressure and drug transport with computational fluid dynamics software (Fluent) based on DCE-MRI data (thesis student) • Hyperpolarized gas MRI; 19F MRI (hypoxia imaging) • Small animal nuclear imaging

  24. CFD model of a solid tumor. Zhao et al. Microvascular Research 73 (2007) 224–236

  25. Small animal nuclear imaging: installed hardware • Micro SPECT (spatial resolution 0.35 mm) • Micro CT (spatial resolution <15 µm), GE • Small animal PET • Dedicated radiopharmacy unit (Prof Devos)

  26. DCE-MRI in patients with metastatic CRC using MS-325 Large liver metastasis

  27. Aims of the project • Study interaction of RT with anti-angiogenic therapy • Verify phenomenon of ‘vascular normalization’ and its importance for therapy planning • Validate functional and molecular imaging as a tool to monitor therapy response • Validate CFD modelling of vascular normalization and drug transport

  28. Methods • Athymic mouse model; human CRC cell line • AZD2171 (Cediranib, 6 mg/kg), RT, or both • Measurements and imaging • Non invasive: DCE-MRI; P1227 • Semi-invasive: IVM • Invasive: pO2, IFP • Modelling of IFP and drug transport using Fluent • Possibility to study nuclear molecular probes in parallel

  29. AZD 2171 Wedge et al. Cancer Res 2005

  30. Contact WP Ceelen, MD, PhD Ghent University Hospital Wim.ceelen@ugent.be M Peeters, MD, PhD Marc.peeters@ugent.be

More Related